Core Viewpoint - The report from Huaxing Securities indicates that JD Health is expected to achieve steady growth in product sales in 2024, supported by an optimized multi-channel layout and enhanced collaboration with well-known pharmaceutical companies [1] Group 1: Product Sales Growth - In 2024, JD Health achieved product sales revenue of 48.8 billion yuan, with the second half of the year impacted by a high base from the previous year [1] - The company is continuously optimizing its multi-channel business layout, enhancing collaboration between online platforms and instant retail, which is expected to lead to steady sales growth in 2025 [1] - JD Health has deepened partnerships with domestic and international pharmaceutical companies, achieving breakthroughs in new drug launches, multi-channel expansion, and digital marketing, while also improving user experience and repurchase rates [1] Group 2: Supply Chain and Healthcare Ecosystem - JD Health is strengthening its pharmaceutical health supply chain capabilities and increasing support for third-party merchants, with over 100,000 third-party merchants on the platform by the end of 2024 [1] - The company is actively promoting online medical insurance payment services, covering 18 cities nationwide and connecting with over 3,000 designated medical insurance pharmacies [1] - JD Health is accelerating the advancement of smart healthcare and digital innovation, launching AI health assistant "Kangkang" and AI psychological companion "Liaoyu Xiaoyuzhou," and collaborating with Wenzhou Medical University First Affiliated Hospital to build a new generation of smart hospitals [1]

Investment Rating - The report maintains a "Buy" rating for the company [1][11]. Core Views - The company's revenue and profit growth for 2024 exceeded Bloomberg consensus expectations, driven by increases in product sales and advertising revenue [7]. - The company has strengthened its self-operated advantages and enhanced the competitiveness of its online platform and instant retail business, achieving complementary advantages across three business models [7]. - The daily average transaction amount reached 1,164.74 million HKD, with over 1.84 million active users by the end of 2024 [7][8]. Financial Performance Summary - For 2024, the company reported revenue of 582 billion RMB, a year-on-year increase of 8.6%, with a gross profit of 133 billion RMB and a gross margin of 22.9% [5][10]. - Adjusted operating profit was 2.6 billion RMB, corresponding to an operating margin of 4.5%, while adjusted net profit reached 4.8 billion RMB, reflecting a year-on-year growth of 15.9% [5][10]. - The company expects revenues of 660 billion RMB in 2025, 741 billion RMB in 2026, and 820 billion RMB in 2027, with adjusted net profits of 4.5 billion RMB, 4.9 billion RMB, and 5.4 billion RMB respectively [9][10]. Market Position and User Engagement - The company has expanded its online medical insurance payment capabilities, significantly enhancing user conversion rates and reducing medication costs for users [7]. - The AI health assistant "KangKang" has served over 30 million users, achieving a problem-solving rate of 70% [8].

Investment Rating - The report maintains a "Buy" rating for JD Health with a target price of HK$55.17, representing a potential upside of 54% from the current price of HK$35.75 [2][15]. Core Insights - JD Health's revenue for 2024 is projected to be RMB 58.16 billion, reflecting an 8.6% year-on-year growth, with a significant profit increase of 94% to RMB 4.16 billion [6][9]. - The company is expected to continue optimizing its product mix, leading to a gross profit increase to RMB 13.31 billion in 2024, up 12.2% [6]. - The report highlights the robust growth in product sales and the optimization of the omnichannel layout, with product sales revenue expected to grow at a compound annual growth rate (CAGR) of 15% from 2025 to 2027 [7]. - JD Health is expanding its healthcare service ecosystem, with service revenue projected to grow at a CAGR of 17% from 2025 to 2027 [8]. Financial Summary - The financial data indicates that JD Health's revenue is expected to reach RMB 67.09 billion in 2025, with a gross profit of RMB 15.86 billion and a net profit of RMB 4.53 billion [9][21]. - The adjusted EPS for 2025 is projected at RMB 1.41, with a growth trajectory leading to RMB 1.97 by 2027 [9][12]. - The report notes a significant increase in operating efficiency, with operating profit expected to rise by 132.9% in 2024 [6][10]. Valuation - The DCF valuation method used in the report results in a target price of HK$55.17, which is based on a WACC of 9.0% and a perpetual growth rate of 3.0% [15][16]. - The target price corresponds to a P/S ratio of 2.4 for 2025, which is below the industry average of 3.1, indicating potential for valuation upside [15][18].